|Videos|May 29, 2020

NCCN Recommendations: Frontline CLL Treatment Options

Episodes in this series

Now Playing

EP. 1 NCCN Recommendations: Frontline CLL Treatment Options

EP. 2 Front-Line Therapy Decision Criteria

EP. 3 Limited-Duration Therapy Based on MRD Testing

EP. 4 Newly Diagnosed CLL: BTK Inhibitor Monotherapy

EP. 5 Developing Clinical Trials for Newly Diagnosed Disease

EP. 6 First-Line Therapy for Treatment-Naïve Patients

EP. 7 BTK Inhibitor Toxicity Management

EP. 8 Oral Oncolytics Versus Intravenous: Safety and Efficacy

EP. 9 Oral Therapy Adverse Events

EP. 10 Intravenous Versus Oral Delivery: Medical Benefits

EP. 11 Pharmacy-Led Oral Chemotherapy Management Programs

EP. 12 Optimizing Success for Community Physicians

EP. 13 Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia

EP. 14 Experts Discuss Treatment Considerations for Chronic Lymphocytic Leukemia

In this Directions in Oncology Pharmacy Insights video series, Alison Duffy, PharmD, BCOP, University of Maryland School of Pharmacy, and Cody Steeves, PharmD, BCOP, Biologics by McKesson, discuss advancements and updates in therapies for chronic lymphocytic leukemia (CLL). This first segment focuses on NCCN recommendations for frontline treatment options.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

NCCN Recommendations: Frontline CLL Treatment Options

Episodes in this series

EP. 1 NCCN Recommendations: Frontline CLL Treatment Options

EP. 2 Front-Line Therapy Decision Criteria

EP. 3 Limited-Duration Therapy Based on MRD Testing

EP. 4 Newly Diagnosed CLL: BTK Inhibitor Monotherapy

EP. 5 Developing Clinical Trials for Newly Diagnosed Disease

EP. 6 First-Line Therapy for Treatment-Naïve Patients

EP. 7 BTK Inhibitor Toxicity Management

EP. 8 Oral Oncolytics Versus Intravenous: Safety and Efficacy

EP. 9 Oral Therapy Adverse Events

EP. 10 Intravenous Versus Oral Delivery: Medical Benefits

EP. 11 Pharmacy-Led Oral Chemotherapy Management Programs

EP. 12 Optimizing Success for Community Physicians

EP. 13 Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia

EP. 14 Experts Discuss Treatment Considerations for Chronic Lymphocytic Leukemia

Related Content

FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC

What Sets VER-01 Apart From Other Cannabis-Derived Pain Therapies?

How Pharmacists Can Strengthen Community CAR T-Cell Programs

mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months

How the PATINA Regimen Advances Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer

Latest CME

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

NEIAP Conference 2026

NEIAP 2026 Annual Forum

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Minimizing Injection Burden: Anti-VEGF Innovation for Retinal Disease Management

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Exploring Immunotherapy Strategies in Endometrial Cancer

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

An American Journal of Managed Care Forum: Bridging Evidence and Access in Advanced Small Cell Lung Cancer

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Expert Insights on the Horizon of HER2-Directed Therapy